

2019 Future of Binge Eating Disorder R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/2DA9658BFADEN.html>

Date: February 2019

Pages: 50

Price: US\$ 2,199.00 (Single User License)

ID: 2DA9658BFADEN

Abstracts

The global demand for Binge Eating Disorder treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Binge Eating Disorder pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Binge Eating Disorder pipeline companies from advancing their products into Phase 3 or Phase 4.

Binge Eating Disorder Report Description-

The 2019 pipeline study on Binge Eating Disorder pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Binge Eating Disorder pipeline compounds.

The Binge Eating Disorder pipeline guide presents information on all active drugs currently being developed for Binge Eating Disorder. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Binge Eating Disorder pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Binge Eating Disorder drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Binge Eating Disorder product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Binge Eating Disorder pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Binge Eating Disorder pipeline report includes-

An overview of Binge Eating Disorder disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Binge Eating Disorder pipeline

Company wise list of Binge Eating Disorder pipeline

Mechanism of Action wise Binge Eating Disorder pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Binge Eating Disorder pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Binge Eating Disorder pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Binge Eating Disorder pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL BINGE EATING DISORDER PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Binge Eating Disorder Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Binge Eating Disorder pipeline, H1- 2019
- 3.5 Mechanism of Action wise Binge Eating Disorder Pipeline Candidates

4 AMYGDALA NEUROSCIENCES INC BINGE EATING DISORDER PIPELINE DETAILS

- 4.1 Amygdala Neurosciences Inc Business Profile
- 4.2 Amygdala Neurosciences Inc Binge Eating Disorder Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography
 - 4.3.6 Type of Molecular Entity

- 4.3.7 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 CHRONOS THERAPEUTICS LTD BINGE EATING DISORDER PIPELINE DETAILS

- 5.1 Chronos Therapeutics Ltd Business Profile
- 5.2 Chronos Therapeutics Ltd Binge Eating Disorder Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 F. HOFFMANN-LA ROCHE LTD BINGE EATING DISORDER PIPELINE DETAILS

- 6.1 F. Hoffmann-La Roche Ltd Business Profile
- 6.2 F. Hoffmann-La Roche Ltd Binge Eating Disorder Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 HEPTARES THERAPEUTICS LTD BINGE EATING DISORDER PIPELINE DETAILS

- 7.1 Heptares Therapeutics Ltd Business Profile
- 7.2 Heptares Therapeutics Ltd Binge Eating Disorder Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 NOVO NORDISK AS BINGE EATING DISORDER PIPELINE DETAILS

- 8.1 Novo Nordisk AS Business Profile
- 8.2 Novo Nordisk AS Binge Eating Disorder Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration
 - 8.3.4 Orphan Drug/Fast Track/Special Designation
 - 8.3.5 Geography
 - 8.3.6 Type of Molecular Entity
 - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9 OMEROS CORP BINGE EATING DISORDER PIPELINE DETAILS

- 9.1 Omeros Corp Business Profile

9.2 Omeros Corp Binge Eating Disorder Drug Details

9.3 Drug Snapshot

9.3.1 Originator

9.3.2 Collaborator/Co-Developer

9.3.3 Route of Administration

9.3.4 Orphan Drug/Fast Track/Special Designation

9.3.5 Geography

9.3.6 Type of Molecular Entity

9.3.7 Current Status

9.4 Drug Overview

9.5 Drug Mechanism of Action

9.6 Clinical/Pre-clinical Trial Details

9.7 Latest Drug Developments

10 OPIANT PHARMACEUTICALS INC BINGE EATING DISORDER PIPELINE DETAILS

10.1 Opiant Pharmaceuticals Inc Business Profile

10.2 Opiant Pharmaceuticals Inc Binge Eating Disorder Drug Details

10.3 Drug Snapshot

10.3.1 Originator

10.3.2 Collaborator/Co-Developer

10.3.3 Route of Administration

10.3.4 Orphan Drug/Fast Track/Special Designation

10.3.5 Geography

10.3.6 Type of Molecular Entity

10.3.7 Current Status

10.4 Drug Overview

10.5 Drug Mechanism of Action

10.6 Clinical/Pre-clinical Trial Details

10.7 Latest Drug Developments

11 SEROPEUTICS LLC BINGE EATING DISORDER PIPELINE DETAILS

11.1 Seropeutics LLC Business Profile

11.2 Seropeutics LLC Binge Eating Disorder Drug Details

11.3 Drug Snapshot

11.3.1 Originator

11.3.2 Collaborator/Co-Developer

- 11.3.3 Route of Administration
- 11.3.4 Orphan Drug/Fast Track/Special Designation
- 11.3.5 Geography
- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 SUNOVION PHARMACEUTICALS INC BINGE EATING DISORDER PIPELINE DETAILS

- 12.1 Sunovion Pharmaceuticals Inc Business Profile
- 12.2 Sunovion Pharmaceuticals Inc Binge Eating Disorder Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 TAKEDA PHARMACEUTICAL CO LTD BINGE EATING DISORDER PIPELINE DETAILS

- 13.1 Takeda Pharmaceutical Co Ltd Business Profile
- 13.2 Takeda Pharmaceutical Co Ltd Binge Eating Disorder Drug Details
- 13.3 Drug Snapshot
 - 13.3.1 Originator
 - 13.3.2 Collaborator/Co-Developer
 - 13.3.3 Route of Administration
 - 13.3.4 Orphan Drug/Fast Track/Special Designation
 - 13.3.5 Geography

- 13.3.6 Type of Molecular Entity
- 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

14. LATEST BINGE EATING DISORDER DRUG PIPELINE DEVELOPMENTS, 2019

15. APPENDIX

- 15.1 About Us
- 15.2 Sources and Methodology
- 15.3 Contact Information

I would like to order

Product name: 2019 Future of Binge Eating Disorder R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/2DA9658BFADEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2DA9658BFADEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

